Drug intelligence / Profile preview

VYR-205

Development stage: Unknown
Lead developer: Vyripharm Biopharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VYR-205 is a precision imaging diagnostic agent being developed by Vyripharm International for the evaluation of Post-Traumatic Stress Disorder (PTSD). Currently in Phase 1 clinical development, the agent is designed to facilitate the objective diagnosis and monitoring of PTSD through advanced medical imaging. Vyripharm specializes in the integration of radiopharmaceuticals and bioinformatics, suggesting that VYR-205 likely functions as a PET or SPECT tracer targeting specific neurological pathways or biomarkers associated with the condition.

Beyond the preview

Go deeper on VYR-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-205.

Explore the full profile